Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

The FDA has approved Dupixent for adult bullous pemphigoid (BP) patients, marking it as the only targeted medicine for the disease; the approval was based on a phase 2/3 trial where Dupixent demonstrated significantly improved sustained disease remission (18.3% vs 6.1% for placebo) and itch reduction, while also reducing oral corticosteroid use. This approval expands Dupixent's application to eight distinct diseases driven by type 2 inflammation and reinforces its safety profile across a broad age range, potentially opening new revenue streams for developers Sanofi and Regeneron.

Analysis

The U.S. Food and Drug Administration's approval of Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP) marks a significant development for its developers Sanofi (SNY) and Regeneron (REGN), positioning it as the sole targeted medicine for this chronic rare skin disease affecting approximately 27,000 US adults with uncontrolled conditions. This approval, granted under priority review and following an orphan drug designation, stems from pivotal Phase 2/3 ADEPT study results where Dupixent demonstrated superior efficacy at 36 weeks over placebo: 18.3% of patients achieved sustained disease remission (versus 6.1% for placebo), 38.3% achieved clinically meaningful itch reduction (versus 10.5% for placebo), and patients on Dupixent required a lower median cumulative oral corticosteroid dose (2.8 grams versus 4.1 grams for placebo). This latest approval expands Dupixent's utility to its eighth distinct disease driven by type 2 inflammation, reinforcing its substantial franchise value and generally broad safety profile, although common adverse events such as arthralgia, conjunctivitis, blurred vision, herpes viral infections, and keratitis were more frequently observed with Dupixent in this elderly BP population. While this news highlights continued pipeline success for Regeneron, the provided text also references an external query from InvestingPro regarding REGN's fair valuation, noting it "wasn't at the top of the list" from its AI algorithms for undervalued stocks, suggesting a potential need to balance specific product advancements with broader market valuation perspectives for the company. Further validating its global potential, regulatory applications for Dupixent in BP are also currently under review in the EU, Japan, and China.

Key Decisions for Investors

• Investors should view this FDA approval as a positive catalyst for Sanofi and Regeneron, likely expanding Dupixent's market share and revenue streams, particularly given its status as the only targeted therapy for bullous pemphigoid.
• Closely monitor upcoming global regulatory decisions for Dupixent in bullous pemphigoid and its subsequent market uptake, as these will be crucial in determining the full commercial impact of this new indication.
• For Regeneron (REGN) investors specifically, it is advisable to weigh this positive product-specific news and Dupixent's growing market against broader valuation assessments, such as the cautionary perspective on REGN's fair value mentioned in the accompanying materials.
• Evaluate the overall risk-reward profile by considering Dupixent's expanding label and strong clinical data, including its reinforced safety profile in an elderly demographic, while remaining cognizant of the specific adverse events reported in the bullous pemphigoid trial.